🏢 官网IRNTRACodex · 实盘不做把握 1/10
北京时间·🕒 发布 20:00:00(美东 08:00)·⟳ 抓取 20:04:23 +4m23s·⚡ 决策 07-30 20:05:11 +48s·89.4 天前
Natera宣布将于8月6日发布2026年二季度业绩
该公告仅披露业绩发布时间和电话会安排，没有收入、利润、指引或经营变化。
📄 原文NTRA↗ 原文
Natera to Report its Second Quarter Results on August 6, 2026
Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator An…
不做 Natera（NTRA.US）
仅为例行业绩发布日期和电话会通知，没有可交易的新增利好或利空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 low ↗
关键理由
- 该公告仅披露业绩发布时间和电话会安排，没有收入、利润、指引或经营变化。
原文全文
展开原文 · 2,248 字
Overview
News
Events & Presentations
Stock Info
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
Analyst Coverage
Financials
Quarterly Results
Proxy Reports
IRS Forms
SEC Filings
Governance
Leadership
Board of Directors
Committee Composition
Governance Documents
Sustainability
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
View all news
Natera to Report its Second Quarter Results on August 6, 2026
07/30/2026
Download
(opens in new window)
PDF 135 KB
AUSTIN, Texas--(BUSINESS WIRE)--
Natera, Inc.
(NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2026, after the market closes on August 6, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information
Event:
Natera’s Second Quarter 2026 Financial Results
Date:
August 6, 2026
Time:
1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In:
1-833-461-5787 (Domestic)
44-808-196-8935 (International)
Conference ID:
786 717 759
Webcast:
https://events.q4inc.com/attendee/786717759
A webcast replay will be available at
investor.natera.com
.
About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit
www.natera.com
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc.,
pr@natera.com
Source: Natera, Inc.
Multimedia Files:
News
Events & Presentations
Stock Info
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
Analyst Coverage
Financials
Quarterly Results
Proxy Reports
IRS Forms
SEC Filings
Governance
Leadership
Board of Directors
Committee Composition
Governance Documents
Sustainability
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
View all news
Natera to Report its Second Quarter Results on August 6, 2026
07/30/2026
Download
(opens in new window)
PDF 135 KB
AUSTIN, Texas--(BUSINESS WIRE)--
Natera, Inc.
(NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2026, after the market closes on August 6, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information
Event:
Natera’s Second Quarter 2026 Financial Results
Date:
August 6, 2026
Time:
1:30 p.m. PT (4:30 p.m. ET)
Live Dial-In:
1-833-461-5787 (Domestic)
44-808-196-8935 (International)
Conference ID:
786 717 759
Webcast:
https://events.q4inc.com/attendee/786717759
A webcast replay will be available at
investor.natera.com
.
About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit
www.natera.com
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc.,
pr@natera.com
Source: Natera, Inc.
Multimedia Files:
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。